Patients & Caregivers
Contact Us
Français
Home
Overview
Major Accomplishments
Working at Merck
Search Jobs, Submit Resume, Log on
Career Choices
Students and recent Grads
Careers Questions
Partners
Company Overview
Community Relations
Frequently Asked Questions
VIOXX® Information Center
Terms and Conditions of Sales
Corporate News
Executive Speeches
Product News
Research & Development News
Media Contact
Newsroom
Corporate News
Photos
Executive Speeches
Product News
CANCIDAS
®
COSOPT
®
COZAAR
®
CRIXIVAN
®
EMEND
®
FOSAMAX
®
FOSAVANCE
®
GARDASIL
®
INTRON A
®
INVANZ
®
ISENTRESS
®
JANUMET
TM
JANUVIA
®
MAXALT
®
PEGETRON
®
PROPECIA
®
PROSCAR
®
ROTATEQ
®
SINEMET
®
SINGULAIR
®
VARIVAX
®
III
VASOTEC
®
VICTRELIS
TM
VIOXX
®
ZOCOR
®
ZOLINZA
®
ZOSTAVAX
TM
EZETROL
®
Research & Development News
Media Contact
JANUMET
TM
Press Releases
Oct 22, 2009
Data Presented at the International Diabetes Federation World Congress Compares JANUMET™ (sitagliptin/metformin HCl) to Metformin Alone as Initial Therapy
Oct 13, 2009
New Type 2 Diabetes Tablet Offers Powerful Blood Glucose Control Without Weight Gain
Monograph / Prescribing Information / Product Information
Click here
Studies
Disease Fact Sheets
Diabetes in Canada
Product Fact Sheets
Photos
B-Roll
JANUMET
TM
What's New
Gardasil
®
Approved To Help Prevent Anal Cancer In Women And Men
Contact
Media contacts
.
Printer friendly
This site is for residents of Canada. / This site was updated on October 26, 2011.
